potassium;1-[2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole;(Z,12R)-12-hydroxyoctadec-9-enoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: potassium;1-[2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole;(Z,12R)-12-hydroxyoctadec-9-enoate
• 化学式: C36H48Cl3KN2O3S
• 分子量: 734.3
• InChiKey: XOJBPSWBWVUUGB-RHAWSBKLSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  7.27
• 重原子数：
  46
• 可旋转键数：
  21
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  104
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF
  申请人：Aciex Therapeutics, Inc.

  公开号：EP2941437A1

  公开（公告）日：2015-11-11
• [EN] PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF<br/>[FR] PRÉPARATIONS D'AGENTS THÉRAPEUTIQUES HYDROPHOBES, LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：ACIEX THERAPEUTICS INC

  公开号：WO2014107231A1

  公开（公告）日：2014-07-10

  The present invention further provides method of preparing nanocrystals or microcrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).